<DOC>
	<DOCNO>NCT01260584</DOCNO>
	<brief_summary>This study conduct determine smoking influence platelet aggregation inhibition ability clopidogrel prasugrel . It also determine smoke effect plasma concentration active metabolite prasugrel active inactive metabolite clopidogrel . The primary hypothesis smoking status influence antiplatelet effect active metabolite concentration clopidogrel impact prasugrel 's antiplatelet effect active metabolite concentration .</brief_summary>
	<brief_title>The Influence Smoking Status Prasugrel Clopidogrel Treated Subjects Taking Aspirin Having Stable Coronary Artery Disease</brief_title>
	<detailed_description>Subjects stratify accord smoking status prior randomize 1 2 treatment sequence : prasugrel 10 mg daily 10 day follow clopidogrel 75 mg daily 10 day clopidogrel 75 mg daily 10 day follow prasugrel 10 mg daily 10 day . There 14-day Washout Period Active Treatment Period 1 ( subject receive first drug sequence ) second Active Treatment Period 2 ( Period 3 ) ( subject receive second drug sequence ) . All subject remain dose aspirin baseline throughout study .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Male female subject &gt; = 18 year &lt; 75 year age ; Weight &gt; = 60 kg ; On aspirin therapy ( 81 mg 325 mg daily ) time screen able maintain consistent aspirin dose regimen baseline visit final study visit ; Subjects contraindication thienopyridine ( ie , prasugrel , clopidogrel , ticlopidine ) history stable atherosclerosis represent CAD , define follow : Chronic stable angina ; Documented prior ACS event &gt; = 30 day screen currently prescribe currently thienopyridine therapy ; Previous coronary revascularization include percutaneous transluminal coronary angioplasty , stent , coronary artery bypass graft ; Coronary Artery Disease ( &gt; = 40 % obstruction ) least one coronary vessel angiography ; Documented history positive stress test ; High coronary artery calcium score ( &gt; = 90th percentile age gender ) determine cardiac compute tomography scan ; Current smoker smoke &gt; = ½ pack per day cigarette NicAlert™ level 6 ; Nonsmokers NicAlert level 0 , 1 , 2 ; Female subject meet one follow : Women childbearing potential negative serum pregnancy test screening , breastfeeding , plan become pregnant study , agree use approve method birth control study . Approved method birth control intrauterine device , diaphragm plus spermicide , female condom plus spermicide . Abstinence , partner 's use condom , partner 's vasectomy , hormonal contraceptive NOT acceptable method contraception ; Women postmenopausal least 1 year hysterectomy , bilateral salpingooophorectomy , tubal ligation least 6 month prior sign Informed Consent Form ( ICF ) ; Subjects competent mental condition provide write informed consent enter study . Subjects receive bare metal stent and/or drugeluting stent within last 12 month ; Subjects angiogram &lt; = 7 day randomization ; Any formal indication use thienopyridine ; Subjects history refractory ventricular arrhythmia ; Subjects history implantable defibrillator device ; Subjects history evidence congestive heart failure ( New York Heart Association Class III ) within 6 month prior screen ; Subjects significant hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 110 mmHg ) either time screen baseline assessment ; Bleeding risk exclusion criterion : Any known contraindication treatment anticoagulant antiplatelet agent ; Prior history clinical suspicion cerebral vascular malformation , intracranial tumor , transient ischemic attack , stroke , recent history ( within 3 month ) head trauma ; Prior history presence significant bleeding disorder ( eg , hematemesis , melena , severe recurrent epistaxis , hemoptysis , hematuria , intraocular bleeding ) ; History ( within last 5 year ) presence gastric ulcer . Previous history duodenal ulcer acceptable must successfully surgically medically treated evidence disease past 6 month ( screen ) ; Prior history abnormal bleeding tendency ( ie , prolonged bleeding dental extraction , tonsillectomy , previous surgical procedure ) ; Known prior history presence thrombocytopenia ( platelet count &lt; 100,000/mm3 ) thrombocytosis ( platelet count &gt; 500,000/mm3 ) recent history ( within 6 month ) hemoglobin &lt; 10 mg/dL ; International normalize ratio ( INR ) &gt; 1.5 activate partial thromboplastin time ( aPTT ) &gt; upper limit normal ( ULN ) laboratory reference range screening ; History major surgery , severe trauma , fracture , organ biopsy within 3 month prior enrollment ; Prior/concomitant therapy exclusion criterion : Subjects take prasugrel , clopidogrel , ticlopidine , cilostazol , dipyridamole , warfarin , heparin , direct thrombin inhibitor , GPIIb/IIIa inhibitor &lt; = 10 day prior randomization study participation ; Use ( plan use ) fibrinolytic agent within 30 day screen study participation ; Subjects receive treatment nonsteroidal antiinflammatory drug cyclooxygenase2 inhibitor exceed 3 dos per week ; Subjects take proton pump inhibitor ( eg , lansoprazole , esomeprazole , omeprazole , pantoprazole , rabeprazole ) &lt; = 10 day prior randomization study participation ; Use plan use herbal supplement &lt; = 10 day prior randomization study participation ; Use plan use follow strong inhibitor various CYP pathway &lt; =10 day prior randomization study participation : ciprofloxacin , cimetidine , fluvoxamine , estradiol , ethinylestradiol , fluconazole , amiodarone , indinavir , nelfinavir , ritonavir , saquinavir , clarithromycin , erythromycin , telithromycin , itraconazole , ketoconazole , fluconazole , nefazodone , grapefruitcontaining product ; Use plan use follow strong inducer various CYP pathway &lt; = 10 day prior randomization study participation : rifampin , barbiturate , carbamazepine , dexamethasone , St. John 's Wort ; Female subject take hormonal contraception hormonal replacement therapy study participation ; General exclusion criterion : Investigative site personnel directly affiliate study immediate family investigative site personnel directly affiliate study . Immediate family define spouse , parent , child , sibling , whether biological legally adopt ; Daiichi Sankyo Eli Lilly employee ; Currently enrol , discontinue within last 30 day , clinical study involve investigational drug device ; Have previously complete withdrawn study ; Women know pregnant and/or receive positive serum pregnancy test result , and/or give birth within past 90 day , and/or breastfeeding ; Results clinical laboratory test time screen judge clinically significant subject , determine Investigator ; Known allergy intolerance aspirin and/or thienopyridines ( prasugrel , clopidogrel , ticlopidine ) ; Evidence significant active neuropsychiatric disease , alcohol abuse , drug abuse , Investigator 's opinion ; Evidence active hepatic disease follow : positive human immunodeficiency virus antibody ; positive hepatitis C antibody ; positive hepatitis B surface antigen ; serum alanine transaminase , aspartate transaminase , gammaglutamyltransferase &gt; = 3 × ULN laboratory reference range ; bilirubin &gt; = 2 × ULN laboratory reference range screening ; Subjects unwilling make available duration study abide research unit policy procedure study restriction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>thienopyridine</keyword>
	<keyword>antiplatelet</keyword>
	<keyword>prasugrel</keyword>
	<keyword>clopidogrel</keyword>
</DOC>